These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6212231)

  • 1. Pharmacokinetic and clinical evaluation of moxalactam in infants and children.
    Latif R; Thirumoorthi MC; Buckley JA; Kobos DM; Aravind MK; Kauffman RE; Dajani AS
    Dev Pharmacol Ther; 1981; 3(4):222-31. PubMed ID: 6212231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxalactam pharmacokinetics in children.
    Romagnoli MF; Flynn K; Siber GR; Goldmann DA
    Antimicrob Agents Chemother; 1982 Jul; 22(1):47-50. PubMed ID: 6214997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam epimer kinetics in children.
    Nahata MC; Durrell DE; Barson WJ
    Clin Pharmacol Ther; 1982 Apr; 31(4):528-32. PubMed ID: 6460588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacokinetic evaluation of moxalactam in infants and children.
    Varghese M; Khan AJ; Quaye G; Patel U; Kumar K; Evans HE
    Chemotherapy; 1982; 28(6):417-20. PubMed ID: 6218971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.
    Kaplan SL; Mason EO; Garcia H; Kvernland SJ; Loiselle EM; Anderson DC; Mintz AA; Feigin RD
    J Pediatr; 1981 Jan; 98(1):152-7. PubMed ID: 6450278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP
    Antimicrob Agents Chemother; 1981 Jun; 19(6):965-71. PubMed ID: 6455967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of probenecid on the pharmacokinetics of moxalactam.
    DeSante KA; Israel KS; Brier GL; Wolny JD; Hatcher BL
    Antimicrob Agents Chemother; 1982 Jan; 21(1):58-61. PubMed ID: 6211135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, excretion, and clinical efficacy of moxalactam in pediatric patients.
    Fujii R
    Rev Infect Dis; 1982; 4 Suppl():S656-63. PubMed ID: 6218579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
    Kemmerich B; Lode H; Belmega G; Jendroschek T; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1983 Mar; 23(3):429-34. PubMed ID: 6303213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of moxalactam in patients with renal insufficiency.
    Lam M; Manion CV; Czerwinski AW
    Antimicrob Agents Chemother; 1981 Mar; 19(3):461-4. PubMed ID: 6454383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxalactam pharmacokinetics during hemodialysis.
    Aronoff GR; Sloan RS; Mong SA; Luft FC; Kleit SA
    Antimicrob Agents Chemother; 1981 Apr; 19(4):575-7. PubMed ID: 6454386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.
    Srinivasan S; Fu KP; Neu HC
    Antimicrob Agents Chemother; 1981 Feb; 19(2):302-5. PubMed ID: 6214989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.
    Schaad UB; McCracken GH; Threlkeld N; Thomas ML
    J Pediatr; 1981 Jan; 98(1):129-36. PubMed ID: 6450277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of moxalactam in patients with malignant disease.
    Estey EH; Weaver SS; Ho DH; Bodey GP
    Antimicrob Agents Chemother; 1981 Apr; 19(4):639-44. PubMed ID: 6454389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.
    Israel KS; Black HR; Brier GL; Wolny JD; DeSante KA
    Antimicrob Agents Chemother; 1982 Jul; 22(1):94-102. PubMed ID: 6214998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Antimicrob Agents Chemother; 1981 Nov; 20(5):567-75. PubMed ID: 6275776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
    Bolton WK; Scheld WM; Spyker DA; Overby TL; Sande MA
    Antimicrob Agents Chemother; 1980 Dec; 18(6):933-8. PubMed ID: 6453555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The penetration of moxalactam into bone (author's transl)].
    Wittmann DH; Schassan HH; Kohler F; Seidel H
    Unfallchirurgie; 1981; 7(3):142-6. PubMed ID: 6455002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.
    Srinivasan S; Neu HC
    Antimicrob Agents Chemother; 1981 Sep; 20(3):398-400. PubMed ID: 6458236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.
    Wise R; Baker S; Livingston R
    Antimicrob Agents Chemother; 1980 Sep; 18(3):369-71. PubMed ID: 6252833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.